Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

40.4 (USD) • At close February 4, 2025
Bedrijfsnaam Crinetics Pharmaceuticals, Inc.
Symbool CRNX
Munteenheid USD
Prijs 40.4
Beurswaarde 3,746,599,040
Dividendpercentage 0%
52-weken bereik 35.51 - 62.53
Industrie Biotechnology
Sector Healthcare
CEO Dr. R. Scott Struthers Ph.D.
Website https://www.crinetics.com

An error occurred while fetching data.

Over Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of

Vergelijkbare Aandelen

Veru Inc. logo

Veru Inc.

VERU

0.56 USD

MannKind Corporation logo

MannKind Corporation

MNKD

5.59 USD

Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

LYEL

0.603 USD

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

13.95 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

97.46 USD

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

112.92 USD

Cassava Sciences, Inc. logo

Cassava Sciences, Inc.

SAVA

2.39 USD

Silk Road Medical, Inc logo

Silk Road Medical, Inc

SILK

27.49 USD

Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT

13.1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)